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Colorectal cancer (CRC) is the third most common and the second deadliest type of cancer 
worldwide, urging the development of more comprehensive models and of more efficient 
treatments. Although the combination of nanotechnology with chemo- and immuno-therapy has 
represented a promising treatment approach, its translation to the clinic has been hampered by 
the absence of cellular models that can provide reliable and predictive knowledge about the in 
vivo efficiency of the formulation. Herein, a 3D model based on CRC multicellular tumor 
spheroids (MCTS) model was developed by combining epithelial colon cancer cells (HCT116), 
human intestinal fibroblasts and monocytes. The developed MCTS 3D model mimicked several 
tumor features with cells undergoing spatial organization and producing extracellular matrix, 
forming a mass of tissue with a necrotic core. Furthermore, monocytes were differentiated into 
macrophages with an anti-inflammatory, pro-tumor M2-like phenotype. For a combined 
chemoimmunotherapy effect, spermine-modified acetalated dextran nanoparticles (NPs) loaded 
with the chemotherapeutic Nutlin-3a (Nut3a) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) were produced and tested in 2D cultures and in the MCTS 3D model. NPs 
were successfully taken-up by the cells in 2D, but in a significant less extent in the 3D model. 
However, these NPs were able to induce an anti-proliferative effect both in the 2D and in the 3D 
models. Moreover, Nut3a was able to partially shift the polarization of the macrophages present 
in the MCTS 3D model towards an anti-tumor M1-like phenotype. Overall, the developed MCTS 
3D model showed to recapitulate key features of tumors, while representing a valuable model to 
assess the effect of combinatorial nano-therapeutic strategies in CRC. In addition, the developed 
NPs could represent a promising approach for CRC treatment. 
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Nowadays, CRC is the third most common and the second deadliest type of cancer worldwide 
[1]. During its progression, CRC tends to metastasize and, despite the intensive effort to develop 
efficient and effective diagnosis tools and anticancer therapies [2, 3], its 5-year survival rate is 
lower than 14% once metastasis occurs [4]. The tumor microenvironment (TME) of CRC is 
directly associated with the progression of this disease and malignancy [5]. Cancer associated 
fibroblasts (CAF), one of the main constituents of the TME stroma, play a preponderant role in 
the tumor, producing ECM and secreting soluble factors (e.g., cytokines), affecting tumor 
proliferation, cellular migration and immunosuppression [6]. Tumor associated macrophages 
(TAMs), another major cellular subset of the TME [7, 8], have crucial implications on tumor 
progression, immunosuppression and ECM remodeling [9]. Macrophages can be polarized 
towards either M1 (pro-inflammatory and anti-tumor) or M2 (anti-inflammatory and pro-tumor), 
exhibiting a continuum of phenotypes, which can change upon different stimuli [10, 11]. 
However, TAMs are mainly M2-like macrophages in the TME and their presence in the cancer 
tissue is generally linked to poor prognosis. The use of single therapies for CRC has promotes 
inconsistent benefits, while inducing toxicity [12]. In order to avoid this problem, the use of 
combinatorial approaches and synergistic tackling of multiple elements in the TME, can promote 
an enhanced effect of the anticancer therapy, diminishing its side effects and avoiding tumor 
recurrence [13, 14].  
Chemoimmunotherapy is a promising combinatorial approach, which has shown killing effect on 
cancer [15]. Depending on their mechanism of action, chemotherapeutics can act by inducing 
tumor cell death in different manners, while simultaneously modulating the immune response. 













immunosuppressive mechanisms, and target/modulate the differentiation and polarization of 
specific cell subpopulations, such as CAFs and TAMS [15, 16]. The simultaneous use of 
immunomodulatory molecules (e.g., cytokines, interleukins, and antibodies) with 
chemotherapeutics can further enhance their impact on the immune system, promoting an 
antitumor immune response.  
 The efficiency of this strategy can still be improved using biomaterials, such as nanoparticles 
(NPs) [17]. NPs represent a powerful tool for drug delivery due to their numerous advantages, 
such as the ability to encapsulate and protect different payloads, control their release, and deliver 
them to specific cells. Thereby, the application of combinatorial strategies, such as 
chemoimmunotherapy based on NPs, has shown improved results in CRC therapy by shifting the 
paradigm of cancer treatment [13, 18]. Nevertheless, despite showing numerous advantages, the 
clinical translation of developed NPs for CRC treatment remains limited [13]. One major hurdle 
is the absence of valuable models capable of predicting the therapeutic outcome in a clinical 
setting. The most frequently used and well-established models for pre-clinical testing are in vitro 
2D cell culture models [19, 20]. These models consist of simple cell monolayers that cannot fully 
mimic the complexity of the TME and recapitulate the myriad of interactions between its 
different cellular and non-cellular components, known to be critical to cell response and clinical 
outcome [21]. Hence, despite the use of NPs and different immunotherapy strategies that have 
shown promising results in vitro, the same outcome has not been observed when these reach the 
clinics. Furthermore, the use of in vivo models is hampered by ethical issues and interspecies 
differences [22]. Thus, it is crucial to develop new models that are able to overcome the 














Multicellular tumor spheroids (MCTS) are three dimensional (3D) cellular self-aggregates, 
which emulate several physiological aspects of human tumors, including the dynamic interplay 
between the TME constituents [23]. These models can be constituted by a heterogenous cellular 
population (e.g., tumor cells, fibroblasts and immune cells) [24, 25], producing their own ECM, 
secreting soluble factors, and changing their genetic profile to a more biologically-relevant state 
[26]. Furthermore, MCTS tend to have a growth pattern characterized by an exponential volume 
increment in the earlier stages followed by a growth plateau, which is observed in some solid 
avascular tumors...[27-29] Moreover, MCTS form a gradient of pH and nutrients, and self-
organize into a structure similar to a non-vascularized tumor [23]. Thereby, due to their intrinsic 
characteristics, MCTS represent a promising approach to screen new developed anticancer 
therapies, namely those based on nanomaterials, providing results similar to the ones obtained in 
vivo [30].   
In this work, a heterotypic MCTS model of CRC was developed to test the efficacy of polymeric 
NPs co-loaded with a chemotherapeutic drug and a cytokine. The MCTS model was constituted 
by epithelial colon cancer cells (HCT116), human intestinal fibroblasts (HIF) and human 
monocytes, which were differentiated mostly into M2-like macrophages. Spermine-modified 
acetalated dextran (Sp-AcDEX) NPs were loaded with the non-genotoxic drug Nutlin-3a (Nut3a) 
and the Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) that were previously 
developed by our group [31]. The effect of the nanosystem on the CRC MCTS 3D model was 
investigated by comparing the cellular association of the developed nanosystem and its ability to 
induce an anti-proliferative effect in 2D monolayers and in the CRC MCTS 3D model. The 
ability of the developed nanosystem to polarize the macrophages present in the CRC MCTS 














2. Experimental Section 
Materials: All the materials and reagents used in this study are described in the Supporting 
Information  
Ethics Statement: Human samples were obtained in agreement with the principles of the 
Declaration of Helsinki. Monocytes were isolated from surplus buffy coats from healthy blood 
donors, kindly provided by the Immunohemotherapy Department of Centro Hospitalar 
Universitário São João (CHUSJ), Porto, Portugal. Procedures were approved by the Centro 
Hospitalar Universitário São João Ethics Committee (protocol 90/19). Blood donors provided 
informed written consent that the byproducts of their blood collections could be used for research 
purposes. 
Synthesis of Spermine-modified Acetalated Dextran: The synthesis of Sp-AcDEX was performed 
as described elsewhere [32-34].Dextran was first oxidized by stirring a solution of dextran (5 g) 
and sodium periodate (1.1 g) in MilliQ-water (20 mL) for 5 h at RT. The obtained oxidized 
dextran was then purified by dialysis in double-distilled water (dd-H2O) with a regenerated 
cellulose membrane (Spectra/Por RC tubin MWCO 3.5 kDa). The partially oxidized dextran was 
lyophilized and purged with N2 in a dry two neck round-bottom flask. Acetalation of dextran was 
performed by dissolving dextran (3 g) with anhydrous dimethyl sulfoxide (DMSO, 30 mL) and 
adding pyridinuim-ptoluenesulfonate (48.6 mg) and 2-methoxypropene (10.6 mL) to the 
solution. After 1 h reaction time, the reaction was quenched with triethylamine (TEA, 1 mL) and 
the resulting acetalated dextran precipitated in dd-H2O (200 mL). AcDEX was collected by 
centrifugation (20000g, 10 min), washed twice with TEA solution (0.01% v/v, pH 8; 100 mL) 













performed by dissolving partially oxidized AcDEX (2 g) in DMSO (20 mL), followed by the 
addition of spermine (4 g). The solution was stirred for 24 h at 50 °C. Afterwards, NaBH4 (1 g) 
was added and the solution was stirred for 24 h at RT. To dissolve the excess of NaBH4, DMSO 
(20 mL) and methanol (10 mL) were added to the flask. Finally, Sp-AcDEX was precipitated 
with MilliQ-water (80 mL), and collected by centrifugation (20000g, 10 min). The polymer was 
washed five times with MilliQ-water (pH 8; 40 mL) by centrifugation and discarding the 
supernatant. The final product was lyophilized, yielding Sp-AcDEX (1.6 g) as a white powder. 
Fabrication of Spermine-modified Acetalated Dextran Nanoparticles: The Sp-AcDEX NPs were 
prepared by a double emulsion technique (water-in-oil-in-water), as described elsewhere [31, 34, 
35]. Sp-AcDEX (12.5 mg) was dissolved in ice-cold dichloromethane (DCM, 250 µL). 
Afterwards, 25 µL of the PBS (pH 7.4) was added dropwise to the polymer solution and the 
mixture was sonicated in an ice bath. Sonication was performed using a probe sonicator (Vibra-
Cell™ ultrasonic processor (Sonics and Materials, Inc., USA) for 30 s of pulsed sonication (10 s 
ON followed by 5 s OFF), with an amplitude of 50%. Next, PVA 2% (w/v; 500 µL) was added 
to the first emulsion and the solution was sonicated again in the same conditions. After 
sonication, the resultant emulsion was poured into a PVA 0.2% solution (w/v; 2.5 mL) and 
stirred (300 rpm) for 3 h to evaporate the remaining DCM. Finally, the NPs were collected by 
centrifugation (20000g, 5 min, 4 °C) and washed twice with HEPES at pH 8 (500 µL) by 
centrifugation and removal of the supernatant. 
To prepare Nut3a-loaded NPs, Nut3a (400 µg) was dissolved in DCM together with Sp-AcDEX. 
GM-CSF was loaded by adding GM-CSF solution (25 µL, 5 ng/mL) instead of PBS to prepare 













FITC loaded NPs were prepared by dissolving FITC in DCM before dissolving Sp-AcDEX in 
the same solution. These NPs were washed six times to ensure the complete removal of free 
FITC from the NPs surface.  
Characterization of the Nanoparticles: NPs average size, PdI and surface charge (ζ-potential) 
was measured by dynamic light scattering (DLS). Prepared NPs were dispersed in HEPES (pH 
7.4, 10×10-3 M) before measuring. To assess the association efficiency (AE) of Nut3a, Nut3a-
loaded NPs (1.25 mg) were dispersed in DMSO (1 mL) and sonicated in ultrasonic bath (5 min) 
to promote dissolution of the NPs and Nut3a release. Following completely dissolution of the 
NPs, the solution was centrifuged (20000g, 5 min, 10 °C) and the supernatant collected and 
analyzed by high performance liquid chromatography (Merck-Hitachi HPLC). All the 
supernatants from NP preparation and washing were also analyzed. For HPLC quantification, a 
Symmetry C18 column, 4.6 × 250 mm, 5 µm (Waters, USA) was used. The mobile phase 
contained 0.1% of  trifluoroacetic acid (TFA) (v/v) and acetonitrile (ACN) 0.1% of TFA (v/v) in 
a ratio of 55:45, respectively, and was set at a flow rate of 1 mL min-1. The detection wavelength 
was 280 nm. 
Cells and Culturing: HCT116 human colorectal cancer cells were obtained from American Type 
Culture Collection (ATCC, USA). Cells were cultured in  Roswell Park Memorial Institute 
(RPMI)-1640 media, supplemented with 10% of heat inactivated FBS, penicillin (100 IU/mL) 
and streptomycin (100 mg/mL), and incubated in 5% CO2 and 95% relative humidity at 37 °C. 
Subculturing was conducted according to the protocol provided by ATCC. HIF were acquired 
from ScienceCell™ Research Laboratories (USA). Cells were cultured in Fibroblasts Medium 
and subcultured according to the protocol provided by the company. Human monocytes were 













Enrichment Cocktail (StemCell Technologies, France), following the manufacturer’s 
instructions.  
Multicellular Tumor Spheroids Formation: MCTS were formed using commercially available 
micro-molds (3D Petri Dish®, from MicroTissues Inc.). First, agarose (2 %, w/v) was dissolved 
in NaCl (0.9 %, w/v) and casted in 3D Petri Dish® micro-molds to form molds with 81 
homogenous circular recesses. Next, the molds were placed in 12-well plates and RPMI media (2 
mL) was added to each well to equilibrate the molds for at least 2 h before cell seeding. 
Afterwards, cells suspension (190 µL; 2.13 × 106 cells/mL), corresponding to ca. 5000 total cells 
per MCTS, were added to the molds and allowed to settle for 30 min, before adding media (2 
mL) to each well. Media was replaced every other day. 
MCTS were produced in monoculture (HCT116 cells), double culture (HCT116 and HIF) and 
triple culture (HCT116, HIF and monocytes), keeping the total number of cells per MCTS at 
5000 cells. Two different densities, 5000 and 10000 cells per MCTS at day 0 were tested for 
monoculture MCTS. Also, three different ratios were tested for HCT116:HIF double culture 
(4:1; 1:1 and 1:4) and one ratio for Monocytes:HCT116:HIF triple culture (4:1:4). When using 
monocytes, media was supplemented with M-CSF (50 ng/mL) for macrophage differentiation.  
Multicellular Tumor Spheroids Size Measurement: At determined time-points (1, 4, 7 and 10 
days), MCTS were monitored, and images were taken using a Brightfield microscopy (ZOE™ 
Fluorescent Cell Imager, Bio-Rad Laboratories). The size was determined by measuring the 
diameter of the MCTS, using ImageJ software. The average size of each condition was 
calculated by performing the average of two diameters measurements per MCTS, evaluated in at 













Cell Metabolic Activity of Multicellular Tumor Spheroids: The metabolic activity of MCTS was 
measured overtime with resazurin assay, as described elsewhere.[36] Briefly, at determined 
timepoints (1, 4, 7 and 10 days), MCTS (≥10 MCTS/condition) were collected from the molds 
and seeded in in 96-well plates. RPMI containing 20% resazurin (v/v; 300 µL) was added to each 
well and incubated in the dark at 37 °C for 2 h. Following the incubation, the media was 
transferred (3 × 100 µL per well) to a 96-well plate with opaque black walls, and the 
fluorescence was measured at the excitation and emission wavelengths of 530 nm and 590 nm, 
respectively, using a SynergyMx™ MultiMode Microplate Reader (BioTek™, USA). The 
obtained fluorescence values were normalized to the number of MCTS per well. All samples 
were done at least in triplicate.  
Multicellular Tumor Spheroids Histological Analysis: At predefined time-points (1, 4, 7 and 10 
days), the media was removed from the wells and MCTS were fixed in 4% of PFA (v/v in PBS; 
2 mL per mold; 30 min; RT). Afterwards, the molds were washed three times with PBS (2 mL), 
and either Histogel™ or agarose 1% (w/v) was added to the top of each mold to fix spheroids 
into the molds. The molds were then embedded in paraffin using an automated embedding 
system (Thermo Scientific™ STP 120 Spin Tissue Processor). Paraffin embedded samples were 
sectioned into 3 µm sections, deparaffinized in xylene and rehydrated in graded alcohol series. 
Staining was performed with H&E.   
Immunohistochemistry of Multicellular Tumor Spheroids: Immunohistochemistry was performed 
as described elsewhere.[36] First, fixed paraffin embedded samples, prepared as described 
above, were sectioned in 5 µm sections, followed by deparaffinization in xylene and rehydration 
in sequentially decreasing ethanol concentrations. Before staining, to retrieve the antigens, 













buffer (10 × 10-3 M, pH 6), at 96 °C for 30 min. Next, samples were washed three times by 
immersing sections in PBS (pH 7.4), under agitation (60 rpm) for 5 min. To permeabilize the 
samples, sections were immersed in triton 0.25% (v/v) at 60 rpm for 10 min and then washed 3 
times, as described above. Before adding antibodies, samples were blocked with 10% of FBS in 
PBS for 1 h at RT. Primary human antibodies (Anti-EpCAM 1:1000, Anti-Vimentin 1:50, Anti-
CD68 1:100 and Anti-Fibronectin 1:200) were added to the samples and incubated overnight, in 
a wet chamber, at 4 °C. Samples were washed three times and the secondary antibodies (at 1:400 
dilution) and DAPI solution diluted in 5% of FBS in PBST (v/v) were incubated in a wet 
chamber, in the dark, for 1 h at RT. Finally, sections were mounted with VectaShield (H-1000, 
Vector), and imaged with Zeiss AxioImager Z1 microscope (Carl Zeiss, Germany) equipped 
with an AxioCam MR ver.3.0. 
Multicellular Tumor Spheroids Characterization by Flow Cytometry: After 7 days of culturing, 
MCTS (~40 MCTS per sample) were collected into an Eppendorf tube, centrifuged (400g, 5 min, 
4°C), and the medium removed. Samples were then washed once with PBS (500 µL) by 
centrifugation, in the same conditions, followed by removal of the supernatant. MCTS were 
dissociated to a single cell suspension by incubation with trypsin-EDTA (0.25 %; 300 µL) for 30 
min at 37 °C, and by pipetting every 5 min during incubation time. Afterwards, complete media 
(1 mL) was added to inactivate the trypsin and cells were centrifuged and washed twice with 
PBS containing 2% of FBS (v/v; 300 µL). Next, cells were resuspended in a solution (100 µL) of 
PBS containing 2% FBS with the primary antibodies (anti-EpCAM 1:400; anti-CD14 1:50 and 
anti-CD90 1:140) and incubated (30 min, 4 °C) in the dark. After incubation, cells were washed 
twice with PBS containing 2% FBS, and resuspended in a solution (100 µL) of PBS 2% FBS 













were washed twice, resuspended in PBS containing 2% FBS (300 µL) and filtered through a 70 
µm pore filter membrane. Samples were analyzed with BD FACSCanto™ II flow cytometer (BD 
Biosciences, USA). All data was processed with FlowJo software (Tree Star, Inc., USA). 
Experiments were performed at least in triplicate.  
Nanoparticles Biocompatibility in 2D Cultures: The biocompatibility of the Sp-AcDEX NPs in 
HCT116, HIF and macrophages was measured by a resazurin-based assay. For HCT116 and 
HIF, 1 × 104 cells per well were seeded in 96-well plates and allowed to attach overnight. After 
that, the medium was removed and different concentrations (50, 100, 200 and 500 µg/mL) of 
NPs suspension in complete medium (100 µL) were added to the cells and incubated for 24 h and 
48 h, at 37 °C under 5% CO2 and 95% of relative humidity. All data was normalized regarding 
the negative control (complete medium), which was considered 100 % viability. At each time-
point, the medium was removed and 100 µL of resazurin 10 % (v/v) in complete media were 
added to each well and incubated for 2 h at 37 °C in the dark. After, fluorescence was measured 
at the excitation and emission wavelengths of 530 nm and 590 nm, respectively, using a 
SynergyMx™ MultiMode Microplate Reader (BioTek™, USA). All samples were done at least 
in quadruplicate.  
To assess the biocompatibility of the macrophages, 1 × 104 monocytes per well were seeded in 
96-well plate and incubated for 7 days in RPMI supplemented with 50 ng/mL of M-CSF to allow 
differentiation into macrophages. After, cells were treated in the same manner as HCT116 and 
HIF.  
Antiproliferative Effect of Nutlin-3a Loaded Nanoparticles and Free Nutlin-3a in 2D Cultures: 
To assess the anti-proliferative effect of Nut3a-loaded NPs and free Nut3a, a resazurin assay was 













aforementioned. Here, instead of bare NPs, cells were incubated with either different 
concentrations of Nut3a-loaded NPs (50, 100, 200 and 500 µg/mL) in complete media or with a 
range of concentrations of free Nut3a (0 to 120 µM) dissolved in complete media with 1 % of 
DMSO.  
2D Cellular Association: 2D cellular association was assessed in HCT116 cells. Firstly, 1 × 104 
cells per well were seeded in 96-well plates and allowed to attach overnight. After that, the 
medium was removed and FITC loaded NPs suspension in complete medium (50 µg/mL, 100 
µL) were added to the cells and incubated for 24 h and 48 h, at 37 °C, under 5% CO2 and 95% of 
relative humidity. At each time-point, the medium was removed, and the cells collected and 
washed twice with PBS. Afterwards, cells were analyzed with BD FACSCanto™ II flow 
cytometer (BD Biosciences, USA). All data was processed with FlowJo software (Tree Star, Inc., 
USA). Experiments were performed at least in triplicate. 
3D Cellular Association: Triple culture MCTS were cultured for 7 days in 12-well plates, as 
described above. At day 7, the medium was removed from the wells and FITC loaded NPs 
dispersed in complete media (200 µg/mL, 2 mL) were added to each well and incubated for 24 
and 48 h at 37 °C under 5% CO2 and 95% of relative humidity, and under agitation on an orbital 
shaker at 50 rpm. After that, MCTS (ca. 80 spheroids/sample) were collected to Eppendorf tubes, 
dissociated to single cell suspension, as previously explained, and washed twice with PBS. 
Samples were resuspended in PBS containing 2 % of FBS and filtered through a 70 µm pore 
filter membrane and analyzed with BD FACSCanto™ II flow cytometer (BD Biosciences, 
USA). All data was processed with FlowJo software (Tree Star, Inc., USA). Experiments were 













Nanoparticles Biocompatibility in 3D Cultures: The biocompatibility of Sp-AcDEX NPs on 
MCTS was evaluated by measuring the ATP content of the cells, which is directly proportional 
to the number of viable cells in culture [37]. First, triple culture MCTS were cultured for 7 days 
in 12-well plates, as described above. At day 7, spheroids were collected and seeded (1 to 3 
spheroids per well) in complete media (100 µL) in Corning® spheroid microplates with 96-wells. 
After that, 100 µL of different concentrations of NPs suspension in complete media (100, 200, 
400 and 1000 µg/mL) were added to each well and incubated at 37 °C, under agitation (30 rpm) 
for 24 h and 48 h. At each time-point, 100 µL of medium was removed and 100 µL of CellTiter-
Glo® 3D Reagent (Promega Corporation, USA) were added. Plates were shaken (100 rpm) for 5 
min and incubated for 25 min at RT. Luminescence was measured using a SynergyMx™ 
MultiMode Microplate Reader (BioTek™, USA). All samples were performed at least in 
quadruplicates.  
Antiproliferative Effect in 3D Cultures: To test the anti-proliferative effect of the Nut3a-loaded 
NPs and free Nut3a in MCTS, a similar study to biocompatibility study was performed. Here, 
instead of bare NPs, 100 µL of Nut3a-loaded NPs dispersed in complete media (100, 200, 400 
and 1000 µg/mL) and free Nut3a dissolved in complete media with 1 % of DMSO (10, 20, 40, 
80, 160 µM) were incubated with MCTS. Viability was assessed by ATP measurements, as 
described above. 
Macrophage Polarization: Triple culture MCTS were cultured for 7 days in 12-well plates. At 
day 7, the medium was removed from the wells and bare NPs and Nut3a NPS dispersed in 
complete media (200 µg/mL, 2 mL), free Nut3a (10 µM, 2 mL) and free GM-CSF (2 ng/mL, 2 
mL) were added to each well and incubated for 48 h at 37 °C under 5% CO2, 95% of relative 













sample) were collected to Eppendorf tubes, dissociated to single cell suspension, as explained 
above, and washed twice with PBS. Next, cells were resuspended in a solution (100 µL) of PBS 
containing 2 % of FBS with anti-CD14 (1:50), anti-CD86 (1:50) and anti-CD163 (1:25) 
antibodies and incubated (30 min, 4 °C) in the dark. After incubation, cells were washed twice 
with PBS containing 2% FBS, resuspended in PBS containing 2% FBS (300 µL) and filtered 
through a 70 µm pore filter membrane. Samples were analyzed with BD FACSCanto™ II flow 
cytometer (BD Biosciences, USA). All data was processed with FlowJo software (Tree Star, Inc., 
USA). Experiments were performed at least in triplicate.  
Statistical Analysis: Results are expressed as mean ± standard deviation (s.d.) of at least three 
independent experiments. Statistical significance was analyzed with two-way analysis of 
variance (ANOVA) with Bonferroni test, with the level of significance set at probabilities of *p 
< 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. All statistical analyses were performed 
using GraphPad Prism (GraphPad Software, San Diego, CA). 
 
3. Results and Discussion 
3.1. Optimization and Characterization of a Heterotypic Triple Culture MCTS model 
One of the major goals of this work was to develop a 3D heterotypic in vitro model, capable of 
closer recapitulating the TME, providing a platform to assess the efficacy of nanomaterials 
designed for chemoimmunotherapy. The co-culture of tumor cells with fibroblasts and 
monocytes in MCTS was prepared to reproduce the 3D structure of tumors and the intrinsic 
interactions between the ECM and different cell types, which are known to affect disease 













To develop this heterotypic triple model, microwell array technology [36, 41-43] was employed 
(Scheme 1). In this technique, cells are seeded in microwells composed of non-adhesive 
hydrophilic hydrogels which inhibit cell-surface interactions, thus promoting cellcell 
interactions and aggregation, leading to the formation of spheroids [44]. With commercially 
available microwell arrays it is possible to simultaneously produce multiple spheroids in a high-
throughput fashion. Here, cells were seeded in agarose micro-molds produced with 3D Petri 
Dish®, and the formation and characteristics of MCTS were analyzed overtime. 
In order to optimize the triple culture MCTS and choose the best culture conditions for their 
formation, we had to study the impact of each cell line in their characteristics. Thus, we have 
firstly prepared and characterized monoculture HCT116MCTS, followed by the gradual 
addition of fibroblasts and monocytes. 
 
 
Scheme 1. Schematic representation of MCTS formation by liquid overlay technique, using 
agarose molds. Image generated with medical art servier. 
 













To produce monoculture of HCT116 MCTS, two different cell densities (5000 and 10000 cells 
per MCTS) were seeded on agarose micro-molds, and MCTS morphology and size, along with 
cell metabolic activity and production of ECM were assessed along 10 days (Error! Reference 
source not found.). As observed by brightfield microscopy (Error! Reference source not 
found.A), at day one (D1), irregular and loose cell aggregates were formed at all initial cell 
densities. Yet, the morphology of these aggregates changed overtime into spherical and more 
compact MCTS. The analysis of MCTS diameter (Error! Reference source not found.B) 
demonstrated a size reduction of approximately 80 µm from D1 to D4, followed by a steady 
growth rate up to D10, which is consistent with the slow proliferation rate observed in compact 
tissue structures [45]. At D10, regardless of the initial cell density, all MCTS reached a similar 
average size of 520 µm. Their metabolic activity was measured overtime through a resazurin-
based assay (Error! Reference source not found.B), and nearly constant levels were 
maintained along 10 days of culture, which are in agreement with the typical steady growth rate 
of MCTS. Additionally, histological analysis of MCTS morphology was performed by 
hematoxylin and eosin (H&E) staining (Error! Reference source not found.C). The H&E 
staining’s corroborated the formation of  loose cell aggregates at D1, and the higher cellular 
organization in  MCTS at D4. Furthermore, after 7 days of culturing, the MCTS developed a 
necrotic core as seen by the presence of condensed chromatin and nuclear disintegration [46, 47] 
(Figure 1C). The development of necrotic cores is typical for spheroids with diameter over 
400500 µm, as the high compaction of such structures promotes the creation of a gradient of 
nutrients and oxygen, with formation of a hypoxic core with dead cells. Additionally,  quiescent, 
viable and proliferative cells are usually located in the outer rim of the spheroids[48-51]. Here, 













respectively (Figure S1). As expected, cells in the outer layer of the spheroid were highly 
proliferative (stained Ki67 positive), and only low amounts of apoptotic cells were observed. 
The increase in necrotic and quiescent cells, coupled with the decrease in proliferative and viable 
cells along time, contributes to the low spheroid growth [48]. Additionally, the expression of 
ECM was analyzed by fibronectin (FN)  staining (Figure S2). As seen, these MCTS were only 
able to synthesize low amounts of ECM, as suggested by the low fibronectin (FN) 
expression(Figure S2). Considering these results, as there were no major differences in spheroid 
formation and characteristics between the tested initial cell densities, we opted to fix the density 
of 5000 cells per spheroid in subsequent studies. Furthermore, as we wanted a spheroid model 
with a necrotic core, in order to represent a more advanced tumor stage, seven days of spheroids 















Figure 1. HCT116 monoculture MCTS formation and characterization along ten days. A) Over 
time brightfield microscopy images of the morphology of MCTS with two different initial 
cultured cell densisites. Scale bar represents 100 µm. B) MCTS diameter and metabolic activity 
evolution over time as function of initial seeding cell density. Values represent mean ± s.d.(n ≥ 
3) C) H&E staining of the different formed MCTS (and respective magnification, portrayed on 














3.1.2. Double culture MCTS 
Fibroblasts are one of the main constituents of the TME, playing a preponderant role in the 
production and remodulation of the ECM and highly affecting cellcell and cellmatrix 
interactions [52, 53]. Moreover, these cells are involved in assisting several cancer cell activities, 
promoting cancer progression and metastasis [54, 55]. Thereby, in order to produce a 3D in vitro 
model capable of better recapitulating a solid tumor, it is important to include fibroblasts in its 
structure. Thus, in the following step, MCTS containing HCT116 cells and human intestinal 
fibroblasts (HIF) were produced. While keeping the total number of initial cells per spheroid at 
5000, two different ratios of HCT116 cells to HIF (1:1 and 1:4) were seeded and culture as 
prolonged for 7 days. Similar to monoculture, the double culture MCTS with 1:1 ratio (Figure 2) 
formed loose and irregular aggregates at D1, which became more spherical and compact with 
time (Figure 2A). However, MCTS with higher fibroblasts ratio (1:4 ratio of HCT116 cells to 
HIF), formed spherical and compact structures at D1. Furthermore, a correlation between the 
ratio of cells and the MCTS diameter was observed, with MCTS containing higher amount of 
fibroblasts having a smaller average diameter (Figure 2B). Irrespective of the cell ratio, all the 
MCTS presented a similar average size of 450 µm after 7 days. Also, the metabolic activity 
profile (Figure 2B) followed a similar trend, with MCTS with less tumor cells showing lower 
activity levels at D1, but with tendency to reach similar activity levels overtime. As seen in 
Figure 2Cand Figure 3, the spatial organization of MCTS altered overtime, with fibroblasts 
(elongated cells, staining positively for vimentin) being localized in the core of the spheroid, 
surrounded by the HCT116 epithelial tumor cells (positively stained with epithelial cell adhesion 













synthesis of endogenous ECM was assessed through immunohistochemical analysis of FN 
expression that, in CRC, was found to be expressed in tumor ECM, but not in healthy tissue [56]. 
FN deposition was directly correlated with the presence of fibroblasts, since MCTS with HIF 
evidenced higher FN deposition than the monoculture ones (Figure 3 and Figure S2). In addition, 
since fibroblasts and ECM are key constituents of the TME, the ratio of 1:4 was selected as the 
optimal condition for subsequent studies.     
 
 
Figure 2. Characterization of HCT116:HIF co-culture MCTS. A) Over time brightfield 













instentinal fibroblasts ratios. Scale bar represents 100 µm. B) MCTS diameter and metabolic 
activity evolution along seven days as function of initial seeding cell density. Values represent 
mean ± s.d. (n ≥ 3). C) H&E staining of the different formed MCTS (and respective  
magnification, portrayed on the right). Scale bar represents 100 µm 
 
Figure 3. Immunofluorescence microscopy images of D7 mono, double and triple co-culture 
MCTS. Representative images of cellular organization within the MCTS: FN (yellow); 
HCT116–EpCAM (green); HIF–vimentin (red); macrophages–CD68 (violet) counterstained with 
DAPI (blue). Scale bars are 50 µm. (Images for the fibronectin expression are the same as the 














3.1.3. Triple culture MCTS 
TAMs are another important subset of cells in the TME that are involved in the CRC progression 
[57, 58]. These immune cells can be found within or near the tumor tissue, and have been 
associated to poor clinical prognosis [59]. TAMs originate either from tissue-resident 
macrophages or from circulating monocytes that upon recruitment, infiltrate into the tumor 
tissue, and subsequently differentiate into M2 macrophages in response to different stimuli from 
the TME [60]. Thus, the last step in production of CRCMCTS was the co-culturing of epithelial 
tumor cells and fibroblasts with monocytes/macrophages. For this purpose, we have opted to use 
peripheral blood-derived human primary monocytes to increase the fidelity of the developed 
model for pre-clinical testing.  
Thereby, freshly isolated monocytes were seeded together with HCT116 and HIF cells at a ratio 
of 4:1:4, respectively, keeping the total number of viable cells seeded per spheroid at 5000. The 
MCTS were cultured for 7 days and characterized as previously. Additionally, in order to 
promote the differentiation of monocytes to macrophages, the medium was supplemented with 
50 ng/ml of macrophage colony stimulating factor (M-CSF).  
As can be observed in Figure 4A, the seeded cells formed compact and spherical MCTS, similar 
to the double co-culture MCTS. However, unlike to the other conditions, in the triple culture, 
small cellular aggregates were found on the vicinity of the MCTS, likely corresponding to 
monocytes which did not penetrate into the MCTS. The diameter of the MCTS increased at a 
constant rate of around 50 µm every three days (Figure 4B), reaching the same size of double 
culture MCTS after 7 days. The metabolic activity profile was also increased overtime. 
Histological analysis (Figure 4C) showed an identical evolution of the spatial conformation of 













being located around them. Furthermore, there was ECM deposition in the core after 4 days of 
culturing, and the formation of a necrotic core after 7 days. Comparing to the mono and double 
culture MCTS, the introduction of monocytes in MCTS constitution resulted in some loss of 
ECM after 7 days, creating an apparently looser structure. According to the literature, TAMs can 
produce proteolytic enzymes capable of digesting the ECM, which further facilitates cancer 
migration and dissemination [61, 62].  
The spatial distribution of the three cell types at D7 was further investigated by 
immunofluorescence microscopy (Error! Reference source not found.), which confirmed the 
location of HIF and HCT116 epithelial cancer cells. Macrophage location was assessed by CD68 
staining, a highly expressed marker in tissue macrophages. While most of macrophages were 
found to be around the MCTS, some could penetrate deeply in the MCTS. This data is in 
accordance with recent published data, showing that CD68+ macrophages are usually located in 
the tumor invasive front area and there is low accumulation intratumorally [63, 64]. As 
previously stated, monocytes and macrophages are recruited by different factors from the TME 
[60]. For example, fibroblasts have shown to secrete cytokines and chemokines that promote the 
recruitment and adhesion of monocytes and promote their differentiation towards M2 
macrophages [58]. Similar to double co-culture MCTS, deposition of FN in the core of the triple 
co-culture MCTS was also observed (Figure 3).  
To further assess the cellular constitution of the triple co-culture MCTS after 7 days in culture, 
the MCTS were disaggregated and the percentage (%) of each cell type was calculated by flow 
cytometry. HCT116 epithelial cancer cells constituted the majority of MCTS cells (90.8±2.4 %), 
while the fibroblasts and macrophages altogether (HIF: 5.6±1.6 %; macrophages: 7.5±1.2%) 













initial seeded cell ratios is attributed to the non-proliferative nature of the macrophages and the 
faster proliferation and higher resistance of tumor cells in comparison with fibroblasts.  
Taking all results in consideration, the triple co-culture MCTS at D7 was chosen as a viable 
model to represent an avascular tumor CRC microenvironment.  
 
 
Figure 4. Comparison between mono, double and triple co-culture MCTS. Images for the mono 













2 for ratio 1:4, respectively. A) Over time brightfield microscopy images of the morphology of 
the mono, double and triple co-culture. Ampliation of brightfield images of the triple co-culture 
spheroids at D1, D4 and D7, in order to better observe the cellular aggregates in the vicinity of 
the spheroid. Scale bars represent 100 µm.  Scale bar represents 100 µm. B) MCTS diameter and 
metabolic activity evolution along 7 days. Values represent mean ± s.d. (n ≥ 3) C) H&E staining 
of the different MCTS (and respective magnification, portrayed on the right). Ampliation of 
sections of mono, double and triple culture spheroids at D7, to observe the core of the spheroid. 
Scale bar represents 100 µm.   
 
3.2. Nanoparticles Production and Characterization  
In this study, polymeric NPs of Sp-AcDEX were prepared by a water-in-oil-in-water double 
emulsion technique, as previously described by our group [31, 65]. The rationale behind the use 
of these specific NPs for a chemoimmunotherapy strategy derives from their advantageous 
characteristics, such as: (i) the ability to encapsulate both hydrophobic and hydrophilic 
molecules, allowing the conjugation of chemotherapeutics and immunomodulators, as Nut3a and 
GM-CSF; (ii) intrinsic immunoadjuvant properties; and (iii) ability to control the release of its 
payloads only upon contact with acidic environment due to the pH-sensitive nature of the 
polymer [31, 66]. 
The physicochemical characteristics of the prepared Sp-AcDEX NPs were analyzed by DLS and 
laser Doppler electrophoresis, and are summarized in Table 1. All the prepared Sp-AcDEX NPs 
had low PdI values, ranging between 0.10 and 0.19, which indicate a relative homogenous size 
distribution. Their Z-average ranged between 200 to 230 nm. Due to the polycationic properties 













positive surface charge (ζ-potential) with ca. +40 mV. The encapsulation of the different 
payloads, Nut3a, GM-CSF and FITC, did not significantly impact the physicochemical 
properties of the NPs. The observed difference on the ζ-potential of FITC NPs compared to the 
bare NPs in Table 3 is attributed to the use of a different batch of polymer to produce FITC NPs. 
However, when compared to bare NPs produced from the same batch, no differences in size, PdI 
and ζ-potential were observed (data not shown).  
 
Table 1. Physicochemical characterization of the bare and loaded Sp-AcDEX NPs used in this 
study. Values represent mean ± s.d. (n=3) 
 
3.3. Cellular Interactions 
One crucial aspect necessary to take into consideration when developing NPs for anticancer 
strategies is the ability of the NPs to be taken-up by the tumor cells. Commonly, cellular 
interactions of the developed nanomaterials are assessed in 2D culture monolayers in vitro, 
which lack critical components of the tumor environment. For example, the absence of ECM, 
which creates a physical barrier and diffusion gradient in the tissue that restricts NPs penetration, 
greatly impacts the cellular interactions and the reliability of the final results [67-69]. Thereby, 
Samples Z-Average [nm] PdI ζ-potential [mV] 
EE [%] 
Nutlin-3a 
Bare NPs 229±2 0.19±0.01 38±2 − 
Nut3a NPs 198±1 0.10±0.02 48±2 84±2 
GM-CSF NPs 208±1 0.14±0.02 41±3 − 
Co-loaded NPs 203±2 0.11±0.01 45±1 86±3 













the use of 3D models that can recapitulate several aspects of the TME is becoming more relevant 
in pre-clinical testing, to obtain better predictive results and facilitate clinical translation[70]. 
Taking this into consideration, we have evaluated the interaction of the developed Sp-AcDEX 
NPs in both a 2D monolayer and on the developed triple co-culture MCTS. Since the developed 
3D model is mostly constituted of HCT116 epithelial cancer cells, and these cells form the outer 
layer of the spheroid (Error! Reference source not found.) where NPs will be in contact at 
first, the tested 2D monolayer was also made of HCT116 cells. FITC-labelled NPs were 
incubated with the 2D model and the triple co-culture MCTS for 24 h and 48 h. At each time-
point, the cells were collected, and the fluorescence intensity was measured by flow cytometry. 
As seen in Figure 5, after 24 h, in the 2D model, ca. 88% of the cells were associated with FITC-
labelled NPs. Unlike in the MCTS, only a reduced number of cells, ca. 26%, were associated 
with the NPs. After 48 h, a slight decrease of 8% in the 2D model and a small increase in the 3D 
model to around 29% was observed. The significant difference in the cellular association 
between the 2D and 3D model can be explained by the conformation of the 3D model, in which 
the cells are tightly packed and have ECM surrounding them, mimicking more closely an 
organotypic structure. Thus, while in 2D monolayer, every cell is in direct contact with the 
FITC-labelled NPs, in the MCTS, the FITC-labelled NPs only have direct contact with the 
external layer of cells. Thus, the interaction of the FITC-labelled NPs with the cells in the deeper 
layers is dependent on the ability of the NPs to penetrate into the MCTS. It is known that the 
physicochemical characteristics of NPs can highly affect their penetration within MCTS. For 
example, NPs larger than 100 nm have shown limited penetration in MCTS, accumulating 
preferentially in the periphery [71, 72]. Additionally, the presence of amines and positive surface 













penetration [72]. Thereby, we hypothesized that Sp-AcDEX NPs, due to their physicochemical 
characteristics, accumulate in the periphery of the MCTS, having low penetration. Although this 
result might look undesirable, several studies have shown that despite these physicochemical 
characteristics impeding tumor penetration, they promote tumor accumulation, leading to a 
higher anticancer efficacy of drug loaded NPs [30, 73]. Moreover, the mean fluorescence 
intensity (MFI) values were similar in both the 2D and 3D cell models, showing a similar 
interaction between the FITC-labelled NPs and the cells in both models. 
 
 
Figure 5. Comparison of cellular association in 2D and 3D cell models of FITC-labelled NPs by 
flow cytometry. FITC-labelled NPs were incubated for 24 h and 48 h. Samples were analyzed 
with two-way ANOVA, followed by Bonferroni’s post-test. Error bars represent mean ± s.d. (n ≥ 
3). 
 
3.4. Biocompatibility of Sp-AcDEX NPs  
To ensure the safety of the developed Sp-AcDEX NPs, their biocompatibility was evaluated in 
both 2D monolayers and in the developed triple co-culture MCTS. The monolayers were 
constituted of HIF, macrophages and HCT116 cells. Four different concentrations of bare NPs 
(50, 100, 200 and 500 µg/mL) were incubated for 24 h and 48 h with the different cell lines, and 










































cell viability was measured at each time-point (Figure 6). As for the 2D models, the NPs showed 
a high safety profile up to 48 h in both HIF and HCT116 cells, with viability values above 80% 
for all tested concentrations. However, the same was not observed for macrophages as, for these 
cells, a dose and time-dependent cytotoxicity occurred. Sp-AcDEX NPs only presented a safety 
profile up to 100 µg/mL in the first 24 h, and up to 50 µg/mL after 48 h. It is hypothesized that 
this higher cytotoxic profile originates from a higher uptake of NPs by macrophages, due to their 
phagocytic nature [74, 75]. Moreover, macrophages express dextran-binding-C-type lectins and 
scavenger receptors, which enhance the uptake of dextran NPs [76-78]. Unlike the other tested 
cells, macrophages derived from human monocytes do not proliferate. Thus, despite the tested 
NPs concentration being the same, there was a high number of NPs per cell, which might explain 
higher sensitivity of these cells to the NPs [75]. When analyzing the biocompatibility in the triple 
co-culture MCTS, all tested concentrations were non-toxic in the first 24 h. After 48 h, a dose 
and time-dependent toxicity was however observed, with viability values being above 70% up to 















Figure 6. In vitro cytotoxicity of Nut3a-loaded NPs by comparison with bare NPs. Bare and 
Nut3a-loaded NPs (50, 100, 200 and 500 µg/mL) were incubated with HIF, macrophages, 
HCT116 cells and triple co-culture MCTS for 24 h and 48 h. At each time point, the viability 
was measured by a resazurin-based assay (in the 2D models) and by measuring the adenosine 
triphosphate (in the 3D model). All the samples were compared with respective negative control. 
Samples were analyzed with two-way ANOVA, followed by Bonferroni’s post-test. All Results 
represent mean ± s.d. (n ≥ 4). 
 
3.5. Antiproliferative Effect of Nut3a-Loaded NPs 
The p53 is a gene capable of regulating the cell cycle, inducing cell cycle arrest, apoptosis or 
senescence upon cellular stress. Thereby, it acts as a tumor suppressor gene, not allowing the 
proliferation of damaged cells [79-81]. In several types of cancer, p53 function plays a 
preponderant role in CRC development and progression, since its function is impaired by 
mutations or overexpression of inhibitors [79, 82]. Several compounds with ability to restore p53 
function have been investigated for CRC treatment. For example, Nut3a is a small molecule that 
acts by inhibiting the p53 proteasomal degradation through the ubiquitin protein ligase murine 
double minute 2 (MDM2) [83]. By acting as a MDM2 antagonist, Nut3a stabilizes and activates 
p53 in CRC cells carrying wild type (wt) p53, promoting tumor growth arrest [79, 84]. 
Furthermore, this compound does not cause DNA damage, which grants its advantage over other 
chemotherapeutics agents, being a potential therapeutic agent for CRC [84]. 
To assess the potential of Nut3a-loaded NPs for CRC treatment, we have performed a similar 
study as for the assessment of the biocompatibility of the NPs. Here, 2D culture monolayers and 













different concentrations of bare NPs, Nut3a-loaded NPs (50, 100, 200 and 500 µg/mL) and free 
Nut3a (1 to 100 µM) for 24 h and 48 h, and their viability was checked at each time-point 
(Figure 6 and S5). The half maximal inhibitory concentration (IC50) values were also calculated 
(Table 2). Considering the Nut3a association efficiency of 86%, 50, 100, 200 and 500 µg/mL of 
Nut3a-loaded NPs corresponded ca. to 2.4, 4.7, 9.4 and 23.5 µM of Nut3a.  
As shown in Figure 6, no toxicity was observed in HIF for all tested concentrations of bare and 
Nut3a-loaded NPs for up to 48 h. For the same cells, a dose and time-dependent toxicity was 
observed for free Nut3a (Figure S3), with the IC50 values of 48.3 and 29.5 µM after 24 and 48 h, 
respectively. Nut3a was shown to induce cellular senescence in fibroblasts, thereby suppressing 
cancer growth [85, 86]. The observed difference between Nut3a-loaded NPs and free Nut3a 
might be attributed to the fact that, while free Nut3a is already soluble in the media, when 
encapsulated in the NPs it will only be released upon degradation of the polymer by contact with 
a more acidic pH [31].  
In macrophages, up to 100 µg/mL of both bare and Nut3a-loaded NPs, Nut3a-loaded NPs 
showed a higher inhibition of cell growth than bare NPs with viability values decreasing from ca. 
85% to 45% after 24 h and from ca. 56% to 26% after 48 h (Figure 6). Moreover, free Nut3a 
only exerted toxicity for concentrations above 20 µM, and no time-dependent toxicity was 
observed (Figure S3). 
When assessed in HCT116 cells, both Nut3a-loaded NPs and free Nut3a exerted a time and dose-
dependent anti-proliferative effect. In the first 24 h, there was no observable reduction in 
viability values for the tested concentrations of Nut3a-loaded NPs, and only high concentrations 
of free Nut3a (>20 µM) could induce growth arrest, with IC50 value of 53.5 µM. After 48 h, 













values reducing ca. 20% for the highest tested concentration, when compared with bare NPs in 
the same concentration. Furthermore, free Nut3a exerted a more pronounced dose-dependent 
effect, reaching an IC50 of 16.8 µM. HCT116 cell line, due to its wtp53, was proven to be 
susceptible to Nut3a treatment [84, 87, 88]. 
Both Nut3a-loaded NPs and free Nut3a have successfully reduced the cell viability of the triple 
co-culture MCTS in a time- and dose-dependent manner (Figure 6 and S5). After 24 h of 
incubation, Nut3a-loaded NPs induced a low inhibition effect, with only the concentrations of 
200 and 500 µg/mL capable of reducing the cell viability by 12% and 15%, respectively, 
compared to bare NPs. Yet, after 48 h, a more pronounced effect was observed, with the viability 
values ranging from 87% to 22%. Furthermore, Nut3a-loaded NPs had a higher anti-proliferative 
effect than free Nut3a in MCTS. This enhanced anti-proliferative effect was observed when 
Nut3a was loaded in NPs, possibly due to the higher accumulation of drug in the MCTS, leading 
to a higher anticancer efficacy [30, 73].  
Although HCT116 cells in 2D culture monolayer were more sensitive to free Nut3a than the 
triple co-culture MCTS after 48 h (Figure S3), the same finding was not observed when Nut3a 
was loaded in Sp-ACDEX NPs (Figure 6). While unexpected, due to a significant lower cellular 
association of the NPs in the MCTS compared to HCT116 2D monolayer (Figure 5), several 
hypothesis can explain this phenomena. One hypothesis might come from the fact that Sp-
AcDEX NPs are pH sensitive and their payload releases only at acidic pH [31, 33, 89]. Thereby, 
since 3D models, unlike the 2D monolayers, recapitulate the creation of an acidic TME, it is 
possible that Nut3a is released faster from the NPs in the MCTS than in 2D culture model. Other 
explanation can possibly come from the inhibition of α5 integrin by Nut3a [90]. The α5β1 













progression and under hypoxia, enhancing cell adhesion to ECM and promoting cell proliferation 
and metastasis [90, 92]. Furthermore, it was shown that Nut3a, by activating p53, decreases the 
expression of α5 integrin and leads to HCT116 apoptosis [90]. Thus, due to the constitution of 
the developed MCTS, which contain HCT116, HIF and FN in its ECM, it is possible that when 
delivering Nut3a to the MCTS, this molecule is also acting through α5 integrin inhibition, 
leading to an enhanced anti-proliferative effect. However, further studies are needed to unveil the 
underlying mechanisms behind this augmented response in 3D comparatively to 2D models. 
Nonetheless, these results show the potential of Nut3a NPs to be used for CRC treatment.  
 
Table 2. Nut3a IC50 values after 24 h and 48 h incubation with HIF, macrophages, HCT116 cells 








3.6. Macrophage Polarization 
Due to the importance of TAMs in the TME and their “plasticity”, TAMs are an attractive target 
for cancer immunotherapy. Thereby, in this study we have analyzed if the developed Nut3a- and 
GM-CSF-loaded NPs could influence the polarization of TAMs towards a more M1-like state. 
For this purpose, D7 triple co-culture MCTS were incubated with bare NPs, co-loaded 
Cells 
Nut3a IC50 (µM) 
24 h 48 h 
HIF 48.3 29.5 
Macrophages 38.5 39.1 
HCT116 53.5 16.8 













(Nut3a+GM-CSF) NPs, free Nut3a, free GM-CSF and only cell culture media, as a control, for 
48 h. Afterwards, MCTS were collected, dissociated into single cell suspension and the 
CD14+macrophage population were analyzed for the ratio of expression of CD163 (M2 marker) 
and of CD86 (M1 marker) (Figure 7 and Figure S4).  
In the control group (cell culture media), the ratio of CD163 to CD86 was 5.1±3.4, indicating a 
higher number of M2-like macrophages, which is correlated with lower overall survival in CRC 
[93]. This was expected as TAMs tend to be polarized to M2 macrophages in the TME [94], 
suggesting that both cancer cells and fibroblasts induce naïve macrophage differentiation into an 
anti-inflammatory state. Free Nut3a, at a concentration of 10 µM, could significantly upregulate 
CD86 and downregulate CD163, resulting in the reduction of CD163 to CD86 ratio to 1.1±0.5. 
Nut3a was previously shown to downregulate M2 gene expression, suppressing the M2 
phenotype through a p53 dependent pathway. Finally, at the tested conditions, bare NPs and co-
loaded NPs also diminished the ratio between CD163+ and CD86+ cells (to 2.1±0.9 and 2.7±1.1, 
respectively), although in a less extent than free Nut3a. The ability of these NPs to induce M1 
polarization can possibly be explained as cationic NPs, including cationic dextran, have been 
shown to induce M1-like polarization and  upregulation of CD86 [95].  
At the tested conditions GM-CSF, which was shown to induce macrophages differentiation to a 
M1 state [96, 97], when incubated with MCTS both in free state or loaded in the NPs, did not 
impact macrophage polarization. It is hypothesized that the amount of GM-CSF used could have 
been insufficient in comparison to the amounts used in other study [96] to produce any effect. 
Moreover,  Notwithstanding, in that  study, TAMs became more pro-inflammatory ex vivo, in 
absence of the pressure herein imposed by the MCTS tumor microenvironment, sustained by 














Figure 7. Macrophage polarization status. Ratio of CD163+ (M2 marker) to CD86+ (M1 
marker) after incubating the triple culture MCTS with media (control), free GM-CSF, free 
Nut3a, bare NPs and co-loaded NPs for 48 h. Samples were analyzed with one-way ANOVA, 









In this study, we have successfully developed a CRCMCTS model constituted by three 






























































constituted by human epithelial colon cancer cells, fibroblasts and primary monocytes, which 
could differentiate into macrophages. This CRC model mimicked different features of the tumor, 
such as ECM production, spatial organization, formation of a necrotic core, and ability to 
differentiate and polarize monocytes to M2-like macrophages. Furthermore, the method of 
production of this model is beneficial for high throughput screening, being adequate for drug 
screening and testing of nanoparticles and chemoimmunotherapy strategies for CRC treatment. 
The developed Sp-AcDEX NPs were biocompatible and successfully taken-up by the epithelial 
cells in both 2D monolayers and in the developed MCTS, despite in a significant lower extent in 
the later one. However, when loaded with Nut3a, these NPs showed an anti-proliferative effect 
both in 2D monolayers and in a higher extent in the developed CRCMCTS model. Finally, 
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